PMID- 12036452
OWN - NLM
STAT- MEDLINE
DCOM- 20030820
LR  - 20221207
IS  - 0910-5050 (Print)
IS  - 1876-4673 (Electronic)
IS  - 0910-5050 (Linking)
VI  - 93
IP  - 5
DP  - 2002 May
TI  - Evaluation of a gemcitabine-doxorubicin-paclitaxel combination schedule through 
      flow cytometry assessment of apoptosis extent induced in human breast cancer cell 
      lines.
PG  - 559-66
AB  - Combination chemotherapy with gemcitabine (Gem), doxorubicin (Dox), and 
      paclitaxel (Pac) (GAT) has been considered attractive as first-line treatment in 
      metastatic breast cancer. We compared the potential of various schedules of GAT 
      to induce apoptosis on MDA-MB-231, MCF7, and T47D human breast cancer cell lines. 
      The extent of apoptotic induction was analyzed by flow cytometry with 
      7-aminoactinomycin D (7AAD) staining. Differences between various schedules in 
      terms of apoptotic induction were statistically significant (P < 0.05). The most 
      effective apoptotic induction regimen was achieved by the sequence: Dox for 16 h 
      followed by Pac + Gem. Schedules employing a 16-h interval between drug 
      administrations induced higher levels of apoptosis in human breast cancer cell 
      lines compared with schedules using a 4-h interval. The therapeutic efficacy of 
      the experimental results shown in this paper has been clinically corroborated in 
      a phase II trial in metastatic breast cancer patients.
FAU - Serrano, Maria J
AU  - Serrano MJ
AD  - Department of Health Sciences, Faculty of Experimental Sciences, University of 
      Jaen, 23071-Jaen, Spain.
FAU - Sanchez-Rovira, Pedro
AU  - Sanchez-Rovira P
FAU - Algarra, Ignacio
AU  - Algarra I
FAU - Jaen, Ana
AU  - Jaen A
FAU - Lozano, Ana
AU  - Lozano A
FAU - Gaforio, Jose J
AU  - Gaforio JJ
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Japan
TA  - Jpn J Cancer Res
JT  - Japanese journal of cancer research : Gann
JID - 8509412
RN  - 0 (Antibiotics, Antineoplastic)
RN  - 0W860991D6 (Deoxycytidine)
RN  - 1CC1JFE158 (Dactinomycin)
RN  - 80168379AG (Doxorubicin)
RN  - P88XT4IS4D (Paclitaxel)
RN  - 0 (Gemcitabine)
SB  - IM
MH  - Antibiotics, Antineoplastic/pharmacology
MH  - Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
MH  - *Apoptosis
MH  - Breast Neoplasms/metabolism/*pathology
MH  - Cell Division
MH  - Cell Survival
MH  - Clinical Trials as Topic
MH  - Dactinomycin/pharmacology
MH  - Deoxycytidine/*administration & dosage/*analogs & derivatives
MH  - Dose-Response Relationship, Drug
MH  - Doxorubicin/*administration & dosage
MH  - Flow Cytometry
MH  - Humans
MH  - Paclitaxel/*administration & dosage
MH  - Time Factors
MH  - Tumor Cells, Cultured
MH  - Gemcitabine
PMC - PMC5927032
EDAT- 2002/05/31 10:00
MHDA- 2003/08/21 05:00
PMCR- 2002/05/01
CRDT- 2002/05/31 10:00
PHST- 2002/05/31 10:00 [pubmed]
PHST- 2003/08/21 05:00 [medline]
PHST- 2002/05/31 10:00 [entrez]
PHST- 2002/05/01 00:00 [pmc-release]
AID - CAE559 [pii]
AID - 10.1111/j.1349-7006.2002.tb01291.x [doi]
PST - ppublish
SO  - Jpn J Cancer Res. 2002 May;93(5):559-66. doi: 10.1111/j.1349-7006.2002.tb01291.x.